C-Telopeptide
Also known as: CTx, C-Terminal Telopeptide, Beta-CrossLaps
What Does C-Telopeptide Measure?
C-Telopeptide (CTx) measures a specific fragment of type I collagen released into the bloodstream when bone is broken down by specialized cells called osteoclasts. Type I collagen is the main protein that forms the structural framework of bone tissue, and as old bone is resorbed during the normal remodeling cycle, small cross-linked fragments called C-terminal telopeptides are released. The beta-CrossLaps test specifically measures the beta-isomer of these fragments, making it a highly specific marker of bone resorption activity.
Why Does C-Telopeptide Matter?
CTx is one of the most sensitive and widely used markers of bone turnover, providing real-time insight into how rapidly bone tissue is being broken down. Elevated CTx levels indicate accelerated bone resorption, which can signal conditions like osteoporosis, osteopenia, or metabolic bone disease before significant bone loss is detectable on a DEXA scan. Clinicians use CTx to assess fracture risk, monitor the effectiveness of anti-resorptive therapies such as bisphosphonates or denosumab, and evaluate bone health in patients with cancer, hormonal disorders, or chronic inflammatory conditions. It is also important in dental and oral surgery planning, as very low CTx levels in patients on long-term bisphosphonate therapy can indicate elevated risk for osteonecrosis of the jaw.
Normal Ranges
Males
Premenopausal reference: 0.016–0.584 ng/mL; Adult males (30–50 years): 0.025–0.573 ng/mL
Females
Premenopausal: 0.016–0.584 ng/mL; Postmenopausal: 0.104–1.008 ng/mL
Children
Varies by age; generally higher than adults due to active bone growth (can exceed 1.0 ng/mL in adolescents)
Causes of High Levels
- Osteoporosis or osteopenia with accelerated bone resorption
- Postmenopausal estrogen deficiency leading to increased osteoclast activity
- Hyperparathyroidism causing excess parathyroid hormone-driven bone breakdown
- Bone metastases from cancers such as breast, prostate, or lung cancer
- Paget's disease of bone with excessive and disorganized bone turnover
- Prolonged glucocorticoid (steroid) use suppressing bone formation while increasing resorption
- Hyperthyroidism accelerating overall bone metabolism
Causes of Low Levels
- Bisphosphonate therapy (e.g., alendronate, zoledronic acid) effectively suppressing osteoclast activity
- Denosumab or other RANK-L inhibitor treatments
How to Improve Your C-Telopeptide
Diet
- Increase calcium intake to 1,000–1,200 mg/day through dairy products, fortified plant milks, leafy greens, and sardines to support bone mineralization
- Ensure adequate dietary protein (1.0–1.2 g/kg body weight) to support collagen synthesis and bone matrix quality
- Consume foods rich in vitamin K2 (fermented cheeses, natto, egg yolks) to promote proper calcium deposition in bone
- Reduce excessive alcohol consumption, which accelerates bone resorption and impairs calcium absorption
- Limit high-sodium and high-caffeine intake, both of which can increase urinary calcium losses
Supplements
- Vitamin D3: 1,000–2,000 IU/day (or as guided by serum 25-OH vitamin D levels) to enhance calcium absorption and suppress PTH
- Calcium carbonate or calcium citrate: 500–600 mg per dose (taken with meals for carbonate, any time for citrate) if dietary intake is insufficient
- Magnesium: 300–420 mg/day to support bone mineral density and vitamin D activation
- Vitamin K2 (MK-7 form): 90–180 mcg/day to activate osteocalcin and reduce calcium loss from bone
- Strontium ranelate or collagen peptides: emerging evidence supports their role in reducing resorption markers, consult a physician before use
Related Biomarkers
Frequently Asked Questions
What is the best time of day to have a CTx blood test?
CTx levels follow a strong diurnal (daily) rhythm and are significantly affected by food intake. Levels are highest in the early morning after an overnight fast and can drop by 20–50% after eating. To get the most accurate and reproducible result, blood should be drawn in the morning after fasting for at least 8 hours. This is especially important when monitoring treatment response over time, as inconsistent timing can make results appear to change when they haven't truly changed.
How quickly do CTx levels change with bisphosphonate treatment?
CTx is one of the earliest responders to anti-resorptive therapy. Within 3–6 months of starting a bisphosphonate like alendronate or after a single infusion of zoledronic acid, CTx levels typically fall by 50–70%. This makes CTx a valuable tool for confirming that a patient is responding to treatment and adhering to their medication regimen. Clinicians often recheck CTx at 3–6 months after starting therapy to assess treatment efficacy.
Can CTx levels predict fracture risk?
Yes, elevated CTx levels are associated with increased fracture risk, independent of bone mineral density measured by DEXA scan. High bone turnover indicated by elevated CTx suggests that bone is being resorbed faster than it can be replaced, weakening its microstructure. Studies show that women with elevated CTx markers have approximately a 2-fold greater risk of hip and vertebral fractures. CTx is most useful when combined with DEXA scan results and clinical risk factors for a comprehensive fracture risk assessment.